Free Trial

Schrödinger (SDGR) Competitors

Schrödinger logo
$17.60
+0.02 (+0.11%)
(As of 10/31/2024 ET)

SDGR vs. EBS, SAGE, ALLK, PTCT, TPTX, RNA, CORT, BHVN, CRNX, and MDGL

Should you be buying Schrödinger stock or one of its competitors? The main competitors of Schrödinger include Emergent BioSolutions (EBS), Sage Therapeutics (SAGE), Allakos (ALLK), PTC Therapeutics (PTCT), Turning Point Therapeutics (TPTX), Avidity Biosciences (RNA), Corcept Therapeutics (CORT), Biohaven (BHVN), Crinetics Pharmaceuticals (CRNX), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "medical" sector.

Schrödinger vs.

Schrödinger (NASDAQ:SDGR) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.

Emergent BioSolutions received 366 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 66.77% of users gave Emergent BioSolutions an outperform vote while only 56.52% of users gave Schrödinger an outperform vote.

CompanyUnderperformOutperform
SchrödingerOutperform Votes
52
56.52%
Underperform Votes
40
43.48%
Emergent BioSolutionsOutperform Votes
418
66.77%
Underperform Votes
208
33.23%

Schrödinger has higher earnings, but lower revenue than Emergent BioSolutions. Schrödinger is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Schrödinger$200.63M6.38$40.72M-$1.88-9.36
Emergent BioSolutions$1.07B0.45-$760.50M-$11.24-0.81

Schrödinger has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Schrödinger presently has a consensus target price of $32.60, indicating a potential upside of 85.33%. Emergent BioSolutions has a consensus target price of $12.00, indicating a potential upside of 32.60%. Given Schrödinger's stronger consensus rating and higher possible upside, research analysts plainly believe Schrödinger is more favorable than Emergent BioSolutions.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Schrödinger
0 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.82
Emergent BioSolutions
1 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.33

Emergent BioSolutions has a net margin of -53.26% compared to Schrödinger's net margin of -100.42%. Emergent BioSolutions' return on equity of -34.38% beat Schrödinger's return on equity.

Company Net Margins Return on Equity Return on Assets
Schrödinger-100.42% -38.38% -26.66%
Emergent BioSolutions -53.26%-34.38%-11.71%

79.1% of Schrödinger shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 8.6% of Schrödinger shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Emergent BioSolutions had 1 more articles in the media than Schrödinger. MarketBeat recorded 4 mentions for Emergent BioSolutions and 3 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.63 beat Emergent BioSolutions' score of 0.45 indicating that Schrödinger is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Schrödinger
0 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Emergent BioSolutions
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Schrödinger beats Emergent BioSolutions on 10 of the 19 factors compared between the two stocks.

Get Schrödinger News Delivered to You Automatically

Sign up to receive the latest news and ratings for SDGR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SDGR vs. The Competition

MetricSchrödingerPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$1.28B$7.12B$5.36B$8.41B
Dividend YieldN/A8.77%5.22%4.20%
P/E Ratio-6.5716.06131.9317.57
Price / Sales6.38258.281,440.1578.36
Price / Cash27.5650.1639.0633.56
Price / Book2.325.674.744.57
Net Income$40.72M$151.16M$115.43M$225.42M
7 Day Performance-0.65%-1.80%-0.86%-0.61%
1 Month Performance-5.15%5.92%3.61%1.50%
1 Year Performance-18.92%39.97%38.90%32.94%

Schrödinger Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SDGR
Schrödinger
2.2386 of 5 stars
$17.60
+0.1%
$32.60
+85.3%
-18.7%$1.28B$200.63M-6.57867Upcoming Earnings
EBS
Emergent BioSolutions
4.3422 of 5 stars
$8.93
-1.4%
$12.00
+34.4%
+376.5%$488.33M$1.05B-0.791,600Upcoming Earnings
Short Interest ↓
SAGE
Sage Therapeutics
4.326 of 5 stars
$8.01
+2.0%
$13.76
+71.8%
-65.4%$482.06M$97.24M-1.08690Earnings Report
Analyst Forecast
Analyst Revision
ALLK
Allakos
4.7379 of 5 stars
$1.31
+10.1%
$1.67
+27.2%
-32.2%$115.99MN/A-0.56131Short Interest ↓
Positive News
High Trading Volume
PTCT
PTC Therapeutics
2.7637 of 5 stars
$40.75
-1.6%
$40.08
-1.7%
+117.0%$3.13B$937.82M-6.461,410Upcoming Earnings
TPTX
Turning Point Therapeutics
N/A$76.01
flat
N/A+0.0%$3.81B$30.83M-11.02250
RNA
Avidity Biosciences
2.2901 of 5 stars
$45.11
-0.1%
$62.67
+38.9%
+749.1%$4.95B$9.56M-15.34190Analyst Forecast
Positive News
CORT
Corcept Therapeutics
4.9174 of 5 stars
$47.28
+0.1%
$65.25
+38.0%
+71.6%$4.92B$569.61M41.84300Earnings Report
Analyst Forecast
News Coverage
BHVN
Biohaven
2.6998 of 5 stars
$52.84
+0.9%
$61.92
+17.2%
+82.7%$4.67B$462.51M-5.77239
CRNX
Crinetics Pharmaceuticals
3.199 of 5 stars
$57.96
-1.3%
$68.55
+18.3%
+92.3%$4.57B$1.39M-15.33210
MDGL
Madrigal Pharmaceuticals
4.5963 of 5 stars
$210.67
+3.8%
$341.75
+62.2%
+71.2%$4.49B$14.64M-8.2690News Coverage
Gap Up

Related Companies and Tools


This page (NASDAQ:SDGR) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners